22303-36-2

Basic information

• Product Name: 2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE
• Synonyms: 2-chloro-n-(4-methoxyphenyl)-acetamid;2-chloro-p-acetanisidid;2-chloro-p-acetanisidide;n-(4-anisyl)chloroacetamide;n-(chloroacetyl)-p-anisidide;n-(p-anisyl)chloroacetamide;2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE;2-CHLORO-N-(4-METHOXYPHENYL)ETHANAMIDE
• CAS NO: 22303-36-2
• Molecular Formula: C₉H₁₀ClNO₂
• Molecular Weight: 199.63
• Mol File: 22303-36-2.mol
• Article Data: 112

Chemical Properties

• Melting Point: 121-122
• Boiling Point: 378.5 °C at 760 mmHg
• Flash Point: 182.7 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 6.26E-06mmHg at 25°C
• Refractive Index: 1.573
• PKA: 12.31±0.70(Predicted)
• CAS DataBase Reference: 2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE(22303-36-2)
• EPA Substance Registry System: 2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE(22303-36-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 22303-36-2(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE is a chemical compound that is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and pharmaceuticals. It is a white crystalline solid that is slightly soluble in water and has a molecular formula of C9H10ClNO2. 2-CHLORO-N-(4-METHOXY-PHENYL)-ACETAMIDE has potential applications in the development of medications for various medical conditions, and its synthesis and properties are of interest to researchers and pharmaceutical manufacturers. Additionally, it is important to handle and store this chemical with care, following proper safety measures and guidelines to prevent any potential hazards or risks associated with its use.

InChI:InChI=1/C9H10ClNO2/c1-13-8-4-2-7(3-5-8)11-9(12)6-10/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 124156-20-3 (4-methoxyphenyl-benzylidene)-carbamic acid methyl ester 
• 79-04-9 chloroacetyl chloride 
• 302931-51-7 (2,4-difluorobenzylidene)(4-methoxyphenyl)amine 
• 104-94-9 4-methoxy-aniline 
• 123-11-5 4-methoxy-benzaldehyde 
• 79-11-8 chloroacetic acid 
• 80676-78-4 tert-butyl((1-(4-methoxyphenyl)vinyl)oxy)dimethylsilane 
• 541-88-8 Chloroacetic anhydride 
• 79-07-2 Chloroacetamide 

Downstream Products

• 2749-56-6 N-(4-methoxy-phenyl)-glycine p-anisidide 
• 536726-20-2 thiocyanato-acetic acid 4-methoxy-benzyl ester 
• 21535-05-7 1,4-bis-(4-methoxyphenyl)piperazine-2,5-dione 
• 3416-18-0 5-hydroxyoxindole 
• 148627-63-8 2-((4-methoxyphenyl)amino)-2-oxoethan-1-aminium 
• 19303-11-8 2-iodo-N-(p-methoxyphenyl)acetamide 
• 3223-77-6 2-chloro-N-(4-methoxy-2-nitrophenyl)acetamide 
• 84489-78-1 (3-chloro-2-chloromethyl-6-methoxy-[4]quinolyl)-(4-methoxy-phenyl)-amine 
• 96-96-8 4-methoxy-2-nitroaniline 
• 108086-40-4 N-(4-methoxyphenyl)-2-(4-oxoquinazolin-3[4H]-yl)acetamide 
• 146606-52-2 3-Amino-thieno[2,3-b]quinoline-2-carboxylic acid (4-methoxy-phenyl)-amide 
• 146606-49-7 2-(3-Cyano-quinolin-2-ylsulfanyl)-N-(4-methoxy-phenyl)-acetamide 
• 116433-57-9 N-(4-Methoxy-phenyl)-2-phenylamino-acetamide 
• 86109-47-9 2-(Benzooxazol-2-ylsulfanyl)-N-(4-methoxy-phenyl)-acetamide 

Relevant articles and documents

Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors

Histone deacetylase inhibitors (HDACIs) offer a promising strategy for cancer therapy. The discovery of potent ferulic acid-based HDACIs with hydroxamic acid or 2-aminobenzamide group as zinc binding group was reported. The halogeno-acetanilide was introduced as novel surface recognition moiety (SRM). The majority of title compounds displayed potent HDAC inhibitory activity. In particular, FA6 and FA16 exhibited significant enzymatic inhibitory activities, with IC50 values of 3.94 and 2.82 μM, respectively. Furthermore, these compounds showed moderate antiproliferative activity against a panel of human cancer cells. FA17 displayed promising profile as an antitumor candidate. The results indicated that these ferulic acid derivatives could serve as promising lead compounds for further optimization.

Docking of disordered independent molecules of novel crystal structure of (N-(4-methoxyphenyl)-2-(3-methyl-2-oxo-3,4-dihydroquinoxalin-1(2H)-yl)acetamide as anti-COVID-19 and anti-Alzheimer's disease. Crystal structure, HSA/DFT/XRD

New quinoxaline derivative, N-(4-methyl-2-nitrophenyl)-2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetamide (NMPOQA= disordered molecules NMPOQAa(50.3% and NMPOQAb(49.7%)) has been synthesized and characterized by ESI-MS, IR, 1H &13C NMR. The geometric parameters of NMPOQA compound which crystallographic structure has been defined by X-ray diffraction have been calculated by Density Functional Theory (DFT), B3LYP, 6-311++G(d,p) basis set. The correlation between experimental and theoretical structure was checked by superimposing the experimental and theoretical structure. Frontier Molecular Orbitals (FMO's) have been created and the gap energy between High Occupied Molecular Orbital (HOMO) and Low Unoccupied Molecular Orbital (LUMO) has been calculated. Additionally, Molecular Electrostatic Potential (MEP) and Hirshfeld studies have been conducted to analyze intermolecular interactions. Interesting molecular docking of NMPOQA and Remdesivir drug with 6M03 was conducted using the same parameters for a fair comparison. A low binding affinity of the NMPOQA (?6.9 kcal/mol) compared to the Remdesivir drug, (?7.1 kcal/mol) and other good reasons make NMPOQA a good candidate against COVID-19. A similar study was calculated with 1EVE producing evidences that suggest NMPOQA may serve as a potential drug for developing Alzheimer's disease (AD) treatment

Triazole sulfonamides derivatives and their use in agriculture

The invention provides a novel triazole sulfonamide derivative and application thereof in agriculture. , The invention relates to a triazole sulfonamides derivative as shown in a formula (I) and a preparation method thereof. I In formula (R)1 And R2 Are each independently hydrogen. C1 -6 Alkyl and the like, R3 Document C3 -8 Cycloalkyl, R4 -SO2 - NRa Rb , SO2 - C1 -6 Alkyl group, SO2 - C3 -8 Cycloalkyl, SO2 - C1 -3 Alkylene - C3 -8 Cycloalkyl, SO2 - Rc , C1 -3 Alkylene - C (＝ O) O-C1 -6 Alkyl or - C1 -3 Alkylene - C (＝ O) - NRd Re , Ra , Rb , Rc , Rd And Re Having the meaning of the invention. The compound, the composition containing the compound and/or the preparation provided by the invention has good bactericidal activity and can be used as a bactericide in agriculture.

Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides

In the present study, a novel generation of selective aldose reductase ALR2 inhibitors with significant hypoglycemic activities was designed and modulated based on rhodanine scaffold joined to an acetamide linker in between two lipophilic moieties. The synthesis of the novel compounds was accomplished throughout simple chemical pathways. Molecular docking was performed on B-cell membrane protein SUR1, aldehyde reductase ALR1 and aldose reductase ALR2 active sites. Compounds 10B, 11B, 12B, 15C, 16C, 26F and 27F displayed the highest hypoglycemic activities with 80.7, 85.2, 87, 82.3, 83.5, 81.4 and 85.3% reduction in blood glucose levels, respectively. They were more potent than the standard hypoglycemic agent repaglinide with 65.4% reduction in blood glucose level. Compounds 12B and 15C with IC50 0.29 and 0.35 μM were more potent than the standard ALR2 inhibitor epalrestat with IC50 0.40 μM. They were selective towards ALR2 over ALR1 134 and 116 folds, respectively. Molecular docking studies matched with the in-vitro and in-vivo results to elucidate the dual activities of both compounds 12B and 15C as potent antagonists for ALR2 over ALR1 and good agonists for the SUR1 protein.